Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis

Genes Chromosomes and Cancer

Volumn 49, Issue 4, 2010, Pages 390-399

  Huh, Jungwon ^a,b   Tiu, Ramon V ^a   Gondek, Lukasz P ^a   O'Keefe, Christine L ^a   Jasek, Monika ^a   Makishima, Hideki ^a   Jankowska, Ania M ^a   Jiang, Ying ^a   Verma, Amit ^c   Theil, Karl S ^d   McDevitt, Michael A ^e   Maciejewski, Jaroslaw P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Ewha Womans University School of Medicine   (South Korea)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME 20Q; CHROMOSOME ARM; CONTROLLED STUDY; CYTOGENETICS; GENE MAPPING; GENOME; HETEROZYGOSITY; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MONOSOMY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 20; COHORT STUDIES; CYTOGENETIC ANALYSIS; FEMALE; GENE DELETION; GENE DOSAGE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MARKOV CHAINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77949372605     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20748     Document Type: Article

References (37)

1. Alvarez S, Cigudosa JC. 2005. Gains, losses and complex karyotypes in myeloid disorders: A light at the end of the tunnel. Hematol Oncol 23:18-25.
2. Asimakopoulos FA, White NJ, Nacheva E, Green AR. 1994. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 84:3086-3094.
3. Bench AJ, Aldred MA, Humphray SJ, Champion KM, Gilbert JG, Asimakopoulos FA, Deloukas P, Gwilliam R, Bentley DR, Green AR. 1998. A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region. Genomics 49:351-362.
4. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJ, Campbell LJ, Bentley DR, Deloukas P, Green AR. 2000. Chromosome 20 deletions in myeloid malignancies: Reduction of the common deleted region, generation of a PAC/ BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19:3902-3913.
5. Brezinova J, Zemanova Z, Ransdorfova S, Sindelarova L, Siskova M, Neuwirtova R, Cermak J, Michalova K. 2005. Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160:188-192.
6. Cook WD, McCaw BJ. 2000. Accommodating haploin sufficient tumor suppressor genes in Knudson's model. Oncogene 19:3434-3438.
7. Douet-Guilbert N, Basinko A, Morel F, Le Bris MJ, Ugo V, Morice P, Berthou C, De Braekeleer M. 2008. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: Characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 87:537-544.
8. Dunbar AJ, Gondek LP, O'Keefe CL, Rataul M, Szpurka H, Sekeres MA, Wang XF, McDevitt MA, Maciejewski JP. 2008. 250K SNP array karyotyping identifies acquired uniparental disomy and homozygous mutation, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 15:10349-10357.
9. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, Skoulakis S, Lillington D, Lister TA, Young BD. 2005. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 65:9152-9154.
10. Gondek LP, Dunbar AJ, Szpurka H, McDevitt MA, Maciejewski JP. 2007. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS One 2:e1225.
11. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. 2008. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534-1542.
12. Griffiths M, Mason J, Rindl M, Akiki S, McMullan D, Stinton V, Powell H, Curtis A, Bown N, Craddock C. 2005. Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations. Leukemia 19:2355-2358.
13. Gupta M, Raghavan M, Gale RE, Chelala C, Allen C, Molloy G, Chaplin T, Linch DC, Cazier JB, Young BD. 2008. Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 47:729-739.
14. Hollings PE. 1994. Molecular heterogeneity at the breakpoints of smaller 20q deletions. Genes Chromosomes Cancer 11:21-28.
15. Huret JL. 2009. Genetics DIM. Available at: http://atlasgeneticsoncology. org/index.html
16. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetsky RD, McDevitt MA, Maciejewski JP. 2009. Loss of heterozygosity 4q42 and TET2 mutations associated with myelodysplatic/myeloproliferative neoplasms. Blood 25:6403-6410.
17. Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS, O'Keefe CL, McDevitt MA, Maciejewski JP. 2009. SNP arraybased analysis of chromosome 17 reveals homozygous TP53 mutations due to copy number-neutral loss of heterozygosity of 17p in advanced MDS and AML with cooperating deletions of chromosomes 5 and 7. Leukemia. DOI: 10.1038/leu.2009.189.
18. Kelaidi C, Eclache V, Fenaux P. 2008. The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 140:267-278.
19. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790.
20. Liu YC, Ito Y, Hsiao HH, Sashida G, Kodama A, Ohyashiki JH, Ohyashiki K. 2006. Risk factor analysis in myelodysplastic syndrome patients with del(20q): Prognosis revisited. Cancer Genet Cytogenet 171:9-16.
21. MacGrogan D, Alvarez S, DeBlasio T, Jhanwar SC, Nimer SD. 2001. Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines. Oncogene 20:4150-4160.
22. Maciejewski JP, Mufti GJ. 2008. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 112:965-974.
23. Melchert M, Kale V, List A. 2007. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 14:123-129.
24. Mitelman F, Johansson B, Mertens F. 2009. Mitelman database of chromosome aberrations in cancer. Available at: http:cgap.nci. nih.gov/chromosomes/ mitelman
25. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea NC, Hayden J, Donaldson N, Aul C, Gattermann N, Giagounidis A, Germing U, List AF, Mufti GJ. 2007. Prevalence and prognostic significance of allelic imbalance by single nucleotide polymorphism analysis in low risk myelodysplastic syndromes. Blood 9:3365-3373.
26. Mrozek K. 2008. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 35:365-377.
27. Payne SR, Kemp CJ. 2005. Tumor suppressor genetics. Carcinogenesis 26:2031-2045.
28. Roulston D, Espinosa R III, Stoffel M, Bell GI, Le Beau MM. 1993. Molecular genetics of myeloid leukemia: Identification of the commonly deleted segment of chromosome 20. Blood 82:3424-3429.
29. Santarosa M, Ashworth A. 2004. Haploinsufficiency for tumour suppressor genes: When you don't need to go all the way. Biochim Biophys Acta 1654:105-122.
30. Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC. 2009. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 113:2022-2027.
31. Shaffer LG, Tommerup N. 2009. ISCN 2009. An International System for Human Cytogenetics Nomenclature. Basel: Karger.
32. Smoley SA, Fink SR, Paternoster SF, Stockero KJ, Nguyen LP, Nguyen PL, Hanson CA, Dewald GW. 2007. Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20q. Cancer Genet Cytogenet 173:144-149.
33. Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP. 2008. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia 3:610-614.
34. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC.
35. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL. 2009. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/ MPN, and AML. Leukemia 23:1343-1345.
36. Wang PW, Eisenbart JD, Espinosa R III, Davis EM, Larson RA, Le Beau MM. 2000. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics 67:28-39.
37. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A, Kurokawa M, Chiba S, Gilliland DG, Koeffler HP, Ogawa S. 2007. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotidepolymorphism genotyping microarrays. Am J Hum Genet 81:114-126.